Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor ... PharmiWeb.com (press release) Novartis today presented results from a pivotal Phase III trial of a treatment regimen including Afinitor® (everolimus) tablets in women with human epidermal growth factor receptor-2 positive (HER2 positive) advanced breast cancer who received prior ... Novartis pivotal Phase III trial shows Afinitor® significantly delays tumor ... NOVARTIS AG : pivotal Phase III trial shows Afinitor® significantly delays ... |
